AZN vs. BBIO: AstraZeneca vs. BridgeBio Pharma Stock Comparison

Company Profile

AstraZeneca (AZN) and BridgeBio Pharma (BBIO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AZN is classified in Pharmaceuticals while BBIO is classified in Biotechnology.

BridgeBio Pharma (BBIO) trades as ordinary local shares, while AstraZeneca (AZN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: AstraZeneca (AZN) earns 22.57% on shareholders’ equity, ranked against its industry; BridgeBio Pharma (BBIO) has no ROE this period.

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile AstraZeneca (AZN) reports 17.68%, ranking against industry peers normally.

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile AstraZeneca (AZN) reports 29.57%, ranking against industry peers normally.

Profitability Metrics

Growth

BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while AstraZeneca (AZN) at 8.63% is closer to the peer norm — faster top-line expansion for BBIO.

Only one side can be read here: AstraZeneca (AZN) reports EPS growth of 45.33%, ranked against its industry; BridgeBio Pharma (BBIO) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both AstraZeneca (AZN) at 1.01 and BridgeBio Pharma (BBIO) at 2.09 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Only one side’s leverage can be read here: AstraZeneca (AZN) carries debt-to-equity ratio of 0.66 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

Financial Strength Metrics

Dividends

BridgeBio Pharma (BBIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a yield of 1.73%, ranking against industry peers normally.

BridgeBio Pharma (BBIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a payout of 45.38%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: AstraZeneca (AZN) trades at 26.37 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

On P/S ratio, both AstraZeneca (AZN) at 4.63 and BridgeBio Pharma (BBIO) at 15.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile AstraZeneca (AZN) reports 5.59, ranking against industry peers normally.

Valuation Metrics